Adocia Reveals Its Financial Calendar for 2025
In an exciting announcement from Adocia, a prominent clinical-stage biopharmaceutical company, the firm has laid out its financial calendar for 2025, outlining significant reporting dates and pivotal meetings with investors. This strategy will help keep the community informed and engaged as the company pioneers innovative solutions in diabetes and obesity treatment.
Key Financial Dates in 2025
Adocia has marked several important dates on its financial calendar that shareholders and investors should note:
February 25, 2025
The company plans to publish its revenue for the fourth quarter of 2024. This initial report sets the stage for understanding Adocia’s financial trajectory as it enters the new year.
April 17, 2025
Following the Q4 report, investors can expect the release of Adocia's financial statements for the entirety of 2024. This comprehensive disclosure will offer insights into the company's performance and position in the market.
May 14, 2025
As Q1 of 2025 comes to a close, Adocia is set to report its revenue for the first quarter, further illuminating how the company is faring in the new fiscal year.
June 11, 2025
This is a significant date for shareholders as it marks the annual shareholders’ meeting, which will discuss the year’s performance and outlook moving forward. This forum offers an excellent opportunity for engagement between the management and the shareholders.
July 23, 2025
In another pivotal moment, the company plans to announce its revenue for the second quarter of 2025, providing another update for investors to consider.
September 25, 2025
This date is reserved for the publication of mid-year financial statements, detailing Adocia's performance as of June 30, 2025. This mid-year look can be crucial for anticipating future performance in the latter half of the year.
October 15, 2025
Concluding the calendar, Adocia will publish its revenue for Q3 2025. This data will be vital for gauging the company’s trajectory approaching the end of the fiscal year.
Investor Engagement and Information
In addition to these key dates, Adocia is committed to maintaining active communication with its investors. The company will regularly engage with the financial community to provide updates on progress and developments.
Comprehensive Corporate Information
For detailed corporate information, such as financial statements and presentations, stakeholders can explore the Investors' section of Adocia's official website.
About Adocia
Adocia focuses on developing cutting-edge therapeutic solutions aimed primarily at metabolic diseases like diabetes and obesity. The company boasts an impressive portfolio supported by four proprietary technology platforms:
- BioChaperone: This technology fosters the development of next-generation insulins and hormone combinations.
- AdOral: Specializing in oral peptide delivery solutions, enhancing accessibility to therapeutic compounds.
- AdoShell: An innovative biomaterial that protects cells during transplantation, initially aimed at pancreatic cell transplants.
- AdoGel: This platform focuses on long-acting drug delivery, seeking to enhance treatment efficacy.
Holding over 25 patent families, Adocia employs around 80 dedicated professionals and is actively making strides in the regulated market of Euronext Paris, listed under ticker symbol ADOC with ISIN: FR0011184241.
Frequently Asked Questions
What is Adocia's main focus as a company?
Adocia specializes in developing therapeutic solutions for metabolic diseases, particularly diabetes and obesity.
When are the key financial updates for 2025?
Key updates include revenue publications and financial statements scheduled from February through October 2025.
How can investors access information about Adocia?
Investors can access financial reports and corporate information by visiting Adocia's official website in the Investors' section.
What technologies does Adocia utilize in its drug development?
Adocia employs multiple proprietary platforms, including BioChaperone, AdOral, AdoShell, and AdoGel, to enhance drug delivery.
Where is Adocia headquartered?
Adocia is based in Lyon and employs around 80 professionals dedicated to advancing its research and development efforts.
